NCT05023837View on ClinicalTrials.gov

Efficacy and Safety of Immunotherapy in Non-small Cell Lung Cancer With Uncommon Histological Type

CompletedOBSERVATIONAL
Enrollment

40

Participants

Timeline

Start Date

March 2, 2018

Primary Completion Date

August 2, 2021

Study Completion Date

August 3, 2021

Conditions
Uncommon Pathological Types of Lung Cancer
Interventions
DRUG

Pembrolizumab 100 MG Injection

Pembrolizumab iv 200mg q21d

Trial Locations (1)

410013

Hunan Cancer Hospital, Changsha

All Listed Sponsors
lead

Hunan Province Tumor Hospital

OTHER

NCT05023837 - Efficacy and Safety of Immunotherapy in Non-small Cell Lung Cancer With Uncommon Histological Type | Biotech Hunter | Biotech Hunter